TAS5315

TAS5315 is a highly potent and selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK), developed by Taiho Pharmaceutical for the treatment of autoimmune and allergic diseases, including rheumatoid arthritis (RA) and chronic spontaneous urticaria (CSU). It acts as an irreversible covalent inhibitor of BTK, blocking B-cell receptor signaling pathways that are implicated in the pathogenesis of these conditions. Preclinical studies demonstrated anti-inflammatory effects in models of arthritis and lupus, with reductions in inflammatory cytokines such as TNF-alpha, IL-1β, and IL-6. Clinical trials have shown dose-dependent BTK occupancy, inhibition of basophil activation, improvements in RA disease activity measures, and efficacy signals in CSU patients refractory to antihistamines. The drug is administered orally

Other names

TAS5315TAS-5315TAS 5315